|
| Studies | Countries | Number of cases | Mean age (SD) | Male/female | Inclusion criteria | Follow-up | Groups | Main findings |
|
| Trink et al. [18] | Italy | 45 | PRP: 28.8, triamcinolone: 27.2, and placebo: 28.1 | 20/25 | (i) AA patients who are generally in good health
(ii) Chronic and recurring illness that has persisted for a minimum of two years
(iii) Presence of 4–6 symmetrical patches of hair loss | 1 year | PRP group, triamcinolone acetonide (TrA) group, and placebo group | (i) Patients in the PRP and TrA groups showed significantly increased hair regrowth compared to the placebo group
(ii) The PRP group had a higher rate of complete remission (60%) at T3 (a specific time point) compared to the TrA group (26.6%)
(iii) In the TrA group, 38% experienced a relapse of the disease at T2 (another specific time point), while no patients in the PRP group had a relapse
(iv) Both the PRP and TrA groups had increased hair regrowth compared to the untreated side of the scalp
(v) In the TrA group, 71% experienced a relapse at T3, while only 31% in the PRP group had a relapse
(vi) 96% of the PRP group experienced regrowth of fully pigmented hair from the beginning of hair growth, while only 25% in the TrA group had the same outcome
(vii) Both groups also reported decreased itching and burning |
|
| El Taieb et al. [13] | Egypt | 90 | PRP: 19.76 (9.09), minoxidil: 22.63 (9.97), and placebo: 20.87 (8.09) | PRP: 15/15, minoxidil: 14/16, and placebo: 10/20 | AA patients aged between 10–40 years, with no therapy for at least 3 months before study | 3 months | PRP group, minoxidil 5% group, and panthenol group (placebo) | (i) PRP was more successful in treating patchy alopecia than alopecia universalis but was found to be ineffective in treating alopecia totalis
(ii) PRP treatment resulted in a significant decrease in short vellus hair, yellow dots, and dystrophic hair, distinguishing it from the effects of minoxidil and the placebo
(iii) PRP treatment showed an earlier and more favorable response in terms of hair regrowth and reduction in short vellus hair and yellow dots compared to other treatments |
|
| Albalat and Ebrahim [12] | Egypt | 80 | PRP: 30.8 (7.5) and steroid: 36.3 (11.3) | PRP: 34/6 and steroid: 34/6 | Healthy persons of both sexes, aged between 17 and 52 years with patchy alopecia | 6 months | PRP group, intralesional corticosteroid (ILC) group | (i) By the 12th week, the PRP group showed more improvement compared to the steroid group, but there was no significant difference between the two. The recurrence rate was 5% in the PRP group and 25% in the steroid group |
|
| Rinaldi et al. [16] | Italy | 60 | 54.32 (8.17) | 37/23 | AA patients aged between 18 and 60 years | 3 months | TR-M-PRP group and placebo group | (i) The TR-M-PRP group showed a complete regression rate of 53.33%, indicating a significant reduction in the severity of alopecia, whereas the placebo group had a complete regression rate of only 3.33% |
|
| Hegde et al. [20] | India | 50 | N/A | N/A | AA patients | 3 months | PRP group and steroid group/placebo | (i) The steroid group exhibited the highest absolute growth and percentage regrowth, followed by the PRP group and the placebo group. There were statistically significant differences in both parameters between the groups
(ii) Dermoscopic grading decreased in all three groups, but the decrease was not statistically significant
(iii) By the end of 3 months, 44% of the PRP patients and 40% of the steroid patients had nearly complete regrowth of hair |
|
| Fawzy et al. [14] | Egypt | 31 | PRP: 31.41 (10.64) and triamcinolone: 34.21 (12.27) | PRP: 13/4 and triamcinolone: 10/4 | AA patients aged 18 years or above | 3 months | PRP and triamcinolone group | (i) Both groups, PRP and triamcinolone, showed a significant decrease in SALT scores (severity of alopecia tool) compared to their baseline levels
(ii) The PRP group demonstrated a significant decrease in AASIS scores (alopecia areata symptom impact scale), while the triamcinolone group did not show a significant decrease
(iii) In the triamcinolone group, there was a statistically significant positive correlation between baseline SALT scores and baseline AASIS scores. However, this correlation was not observed in the PRP group
(iv) There was also a statistically significant correlation between baseline and final AASIS scores and baseline and final SALT scores in the PRP group
(v) Both groups showed statistically significant improvement in trichoscopic findings. There was a statistically significant link between the dystrophic alterations score and the percentage of improvements in SALT and AASIS scores |
|
| Ragab et al. [15] | Egypt | 60 | PRP: 30.2 (11.49), fractional carbon dioxide laser (FCL): 34.2 (14.55), and microneedling MND: 29 (7.64) | PRP: 18/2, FCL: 14/6, and MND: 16/4 | AA patients | 6 months | PRP group, FCL group, and microneedling group | (i) In the PRP, FCL, and MND groups, 80%, 80%, and 70% of patients, respectively, experienced improvement in their condition
(ii) There was no significant difference observed in the degree of improvement between the three groups
(iii) All patients who showed improvement in their condition maintained these improvements without any recurrence or regression during the follow-up period
(iv) There was no significant relationship found between the degree of improvement at the end of the treatment sessions and factors such as patient age, disease duration, patient sex, or the distribution of AA |
|
| Rinaldi et al. [17] | Italy | 160 | PRP: 51.84 (9.54) and placebo: 53.12 (6.18) | PRP: 44/36 and placebo: 37/43 | Patients between the ages of 18 and 60 who have had AA for at least three years and whose AA has a SALT score between S2 and S5 | 3 months | TR-PRP group and placebo group | (i) After two months of treatment, the PRP group showed a significant improvement from the baseline SALT score
(ii) In contrast, there was no significant change observed from the baseline to T1 and T2 in the placebo group
(iii) Only 5% of the placebo group experienced complete regression of their condition
(iv) In the PRP group, 47.5% of patients achieved complete regression, indicating a significant reduction in the severity of their condition
(v) In addition, 13.75% of the PRP group achieved partial regression, while 6.25% did not respond to the treatment at all |
|
| Thyvalappil et al. [19] | India | 40 | N/A | PRP: 55%/45% and triamcinolone: 90%/10% | (i) The study enrolled patients who had not received any treatment for their AA in the three months prior to the study
(ii) The participants in the study were required to be older than 18 years of age | 12 weeks | PRP group and triamcinolone group | (i) There was no statistically significant difference in SALT scores between the two groups at other time points
(ii) The treatment response was better in the PRP group compared to the triamcinolone group
(iii) The hair regrowth scale did not show a significant difference between the two groups
(iv) In the PRP group, 12.5% of patients had an excellent response, while none of the patients in the triamcinolone group had an excellent response
(v) In terms of a good response, 31.3% of the PRP group and 18.8% of the triamcinolone group showed improvement
(vi) On the other hand, a poor response was observed in 18.8% of the PRP group and 43.8% of the triamcinolone group |
|
